Inhibitors of myostatin-and proteasome-dependent signaling for attenuating muscle wasting

Recent Patents on Regenerative Medicine

Volumn 1, Issue 3, 2011, Pages 284-298

  Sakuma, Kunihiro ^a   Yamaguchi, Akihiko ^b  

^a TOYOHASHI UNIVERSITY OF TECHNOLOGY   (Japan)

^b HEALTH SCIENCES UNIVERSITY OF HOKKAIDO   (Japan)

Author keywords

Muscle wasting; Muscular dystrophy; Myostatin; Proteasome; Sarcopenia; Skeletal muscle

Indexed keywords

EID: 84866552856     PISSN: 22102965     EISSN: 22102973     Source Type: Journal    
DOI: 10.2174/2210296511101030284     Document Type: Article

References (189)

1. Rosenberg I. Summary comments. Am J Clin Nutr 1989; 50: 1231-1233.
2. Roubenoff R, Heymsfield SB, Kehayias JJ, Cannon JG, Rosenberg H. Standardization of nomenclature of body composition in weight loss. Am J Clin Nutr 1997; 66: 192-196.
3. Roubenoff R, Kehayias J. The meaning and measurement of lean body mass. Nutr Rev 1991; 46: 163-175.
4. Keys A, Brozek J, Henschel A, Mickelsen O, Taylor HL, Simonson E, et al. The Biology of Human Starvation. University of Minnesota Press: Minneapolis, MN 1950.
5. Hughes V, Roubenoff R. Sarcopenia: Current concepts. J Gerontol Med Sci 2000; 55A: M716-M724.
6. Wong-Kisiel LC, Kuntz NL. Two siblings with limb-girdle muscular dystrophy type 2E responsive to deflazacort. Neuromuscul Disord 2010; 20: 122-124.
7. Biggar WD, Harris VA, Eliasoph L, Alman B. Long-term benefits of deflazacort treatment for boys with Duchenne muscular dystrophy in their second decade. Neuromusc Disord 2006; 16: 249-255.
8. Gordon KE, Dooley JM, Sheppard KM, Macsween J, Esser MJ. Impact of bisphosphonates on survival for patients with Duchenne muscular dystrophy. Pediatrics 2011; 127: e353-358.
9. Allamand V, Guicheney P. Merosin-deficient congenital muscular dystrophy, autosomal recessive (MDC1A, MIM no.156225, LAMA2 gene coding for alpha2 chain of laminin). Eur J Hum Genet 2002; 10: 91-4.
10. Kanagawa M, Toda T. The genetic and molecular basis of muscular dystrophy: Roles of cell-matrix linkage in the pathogenesis. J Human Genet 2006; 51:915-926.
11. Durbeej M, Campbell KP. Muscular dystrophies involving the dystrophin-glycoprotein complex: An overview of current mouse models. Curr Opin Genet Dev 2002; 12: 349-361.
12. Voit T, Tome FS. The congenital muscular dystrophies. In Engel AG and Franzini-Armstrong C. (eds) Myology, McGrawHill, New York, 2004, pp. 1203-1238.
13. Ibraghimov-Beskrovnaya O, Ervasti JM, Leveille CJ, Slaughter CA, Sernett SW, Campbell KP. Primary structure of dystrophinassociated glycoproteins linking dystrophin to the extracellular matrix. Nature 1992; 355: 696-702.
14. Song WK, Wang W, Foster RF, Bielser DA, Kaufman SJ. H36-alpha 7 is a novel integrin alpha chain that is developmentally regulated during skeletal myogenesis. J Cell Biol 1992; 117: 643-657.
15. Xiong Y, Zhou Y, Jarrett HW. Dystrophin glycoprotein complexassociated Gbetagamma subunits activate phosphatidylinositol-3-kinase/Akt signaling in skeletal muscle in a laminin-dependent manner. J Cell Physiol 2009; 219: 402-414.
16. Hershko A, Ciechanover A. Mechanisms of intracellular protein breakdown. Annu Rev Biochem 1982; 51: 335-364.
17. Rocha CT, Hoffman EP. Limb-girdle and congenital muscular dystrophies: Current diagnostics, management, and emerging technologies. Curr Neurol Neurosci Rep 2010; 10: 267-276.
18. Straub V, Bushby K. Therapeutic possibilities in the autosomal recessive limb-girdle muscular dystrophies. Neurotherapeutics 2008; 5; 619-626.
19. Candow DG, Chilibeck PD. Differences in size, strength, and power of upper and lower body muscle groups in young and older men. J Gerontol A Biol Sci Med Sci 2005; 60: 148-156.
20. Melton 3rd LJ, Khosla S, Crowson CS, O'Fallon WM, Riggs BL. Epidemiology of sarcopenia. J Am Geriat Soc 2000; 48: 625-630.
21. Baumgartner RN, Waters DL, Gallagher D, Morley JE, Garry PJ. Predictors of skeletal muscle mass in elderly men and women. Mech Ageing Dev 1999; 107: 123-136.
22. Short KR, Nair KS. The effect of age on protein metabolism. Curr Opin Clin Nutr Metab Care 2000; 3: 39-44
23. Short KR, Vittone JL, Bigelow JL, Proctor DN, Nair KS. Age and aerobic exercise training effects on whole body and muscle protein metabolism. Am J Physiol Endocrinol Metab 2004; 286: E92-E101.
24. Larsson L. Morphological and functional characteristics of the ageing skeletal muscle in man. A cross-sectional study. Acta Physiol Scand Suppl 1978; 457: 1-36.
25. Verdijk LB, Koopman R, Schaart G, Meijer K, Savelberg HH, van Loon LJ. Satellite cell content is specifically reduced in type II skeletal muscle fibers in the elderly. Am J Physiol Endocrinol Metab 2007; 292: E151-E157.
26. Verdijk LB, Gleeson BG, Jonkers RAM, Meijer K, Savelberg HHCM, Dendale P, et al. Skeletal muscle hypertrophy following resistance training is accompanied by a fiber type-specific increase in satellite cell content in elderly men. J Gerontol A Biol Sci Med Sci 2009; 64: 332-329.
27. Brack AS, Bildsoe H, Hughes SM. Evidence that satellite cell decrement contributes to preferential decline in nuclear number from large fibres during murine age-related muscle atrophy. J Cell Sci 2005; 118: 4813-21.
28. Collins CA, Zammit PS, Ruiz AP, Morgan JE, Partridge TA. A population of myogenic stem cells that survives skeletal muscle aging. Stem Cells 2007; 25: 885-894.
29. Day K, Shefer G, Shearer A, Yablonka-Reuveni Z. The depletion of skeletal muscle satellite cells with age is concomitant with reduced capacity of single progenitors to produce reserve progeny. Dev Biol 2010; 340: 330-343.
30. Conboy IM, Conboy MJ, Smythe GM, Rando TA. Notch-mediated restoration of regenerative potential to aged muscle. Science 2003; 302: 1575-1577.
31. Wagners AJ, Conboy IM. Cellular and molecular signatures of muscle regeneration: Current concepts and controversies in adult myogenesis. Cell 2005; 122: 659-667.
32. Lexell J. Ageing and human muscle: Observations from Sweden. Can J Appl Physiol 1993; 18: 2-18.
33. Roubenoff R, Hughes VA. Sarcopenia: Current concepts. J Gerontol A Biol Sci Med Sci 2000; 55: M716-24.
34. Sakuma K, Akiho M, Nakashima H, Akima H, Yasuhara M. Agerelated reductions in expression of serum response factor and myocardin-related transcription factor A in mouse skeletal muscles. Biochim Biophys Acta Mol Basis Dis 2008; 1782: 453-461.
35. Sakuma K, Yamaguchi A. Molecular mechanisms in aging and current strategies to counteract sarcopenia. Curr Aging Sci 2010; 3: 90-101.
36. Sakuma K, Yamaguchi A. Sarcopenia: Molecular mechanisms and current therapeutic strategy. Cell Aging (in press). NY: Nova Science Publisher 2011.
37. Thomson DM, Gordon SE. Impaired overload-induced muscle growth is associated with diminished translational signaling in aged rat fast-twitch skeletal muscle. J Physiol 2006; 574: 291-305.
38. Dalton, J.T., Miller, D.D., Yin, D., He, Y. Treating androgen decline in aging male (ADAM)-associated conditions with SARMS. US20100137430 (2010).
39. Dalton, J.T., Miller, D.D., Steiner, M.S., Veverka, K.A., Gao, W. Treating being prostate hyperplasia with SARMS. US20100280107 (2010).
40. Thorner, M.O. Methods for treating sarcopenia with a growth hormone secretagogue. US20070219226 (2007).
41. Draghia-Akli, R., Schwartz, R. J. Composition and method to alter lean body mass and bone properties in a subject. US20090292107 (2009).
42. Wolfe, R., Troup, J., Deutz, N.E.P. Compositions and methods for increasing muscle mass, strength, and functional performance in the elderly. US20100286023 (2010).
43. Rathmacher, J., Fuller, J. Jr., Baier, S., Nissen, S., Abumrad, N. Nutritional intervention for improving muscular function and strength. US20100179112 (2010).
44. Kambadur, R., Sharma, M., Hennebry, A., Senna Salerno, D. M. M. Use of myostatin (GDF-8) antagonists for treatment of sarcopenia (age-related muscle-wasting). US20090136481 (2009).
45. Kambadur, R., Sharma, M., Hennebry, A., Senna Salerno, D. M. M. Muscle regeneration composition and uses therefore. US20070190056 (2007).
46. Evans WJ, Morley JE, Argilés J, Bales C, Baracos V, Guttridge D, et al. Cachexia: a new definition. Clin Nutr 2008; 27: 793-793
47. Fearon KCH. Cancer cachexia: Developing multimodal therapy for a multidimensional problem. Eur J Cancer 2008; 44: 1124-1132.
48. Tisdale MJ. Mechanisms of cancer cachexia. Physiol Rev 2009; 89: 381-410.
49. Deans C, Wigmore SJ. Systemic inflammation, cachexia and prognosis in patients with cancer. Curr Opin Clin Nurs Metal Care 2005; 8: 265-269.
50. Mitch WE, Price SR. Transcription factors and muscle cachexia: Is there a therapeutic target? Lancet 2001; 357: 734-735.
51. Kumar NB, Kazi A, Smith T, Crocker T, Yu D, Reich RR, et al. Cancer cachexia: Traditional therapies and novel molecular mechanism-based approaches to treatment. Curr Treat Options Oncol 2010; 11: 107-117.
52. Anker SD, Ponikowski P, Varney S, Chua TP, Clark AL, Webb-Peploe KM, et al. Wasting as independent risk factor for mortality in chronic heart failure. Lancet 1997; 349: 1050-1053.
53. Pu CT, Johnson MT, Forman DE, Hausdorff JM, Roubenoff R, Foldvari M, et al. Randomized trial of progressive resistance training to counteract the myopathy of chronic heart failure. J Appl Physiol 2001; 90: 2341-50.
54. Lopez AD, Murray CC. The global burden of disease, 1990-2020. Nat Med 1998; 4: 1241-1243.
55. Wouters EF. Management of severe COPD. Lancet 2004; 364: 883-895.
56. Wouters EF. Local and systemic inflammation in chronic obstructive pulmonary disease. Proc Am Thorac Soc 2005; 2: 26-33.
57. MacDougall JD, Green HJ, Sutton JR, Coates G, Cymerman A, Yung P, et al. Operation Everest II: Structural adaptations in skeletal muscle in response to extreme stimulated altitude. Acta Physiol Scand 1991; 142: 421-427.
58. Pitta F, Troosters T, Spruit MA, Probst VS, Decramer M, Gosselink R. Characteristics of physical activities in daily life in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2005; 171: 972-977.
59. Strong MJ. Amyotrophic lateral sclerosis: Contemporary concepts in etiopathogenesis and pharmacotherapy. Exp Opin Investig Drugs 2004; 13: 1593-1614.
60. Brujin LI, Miller TM, Cleveland DW. Unraveling the mechanisms involved in motor neuron degeneration in ALS. Annu Rev Neurosci 2004; 27: 723-749.
61. Reaume AG, Elliott JL, Hoffman EK, Kowall NW, Ferrante RJ, Siwek DF, et al. Motor neurons in Cu/Zn superoxide dismutasedeficient mice develop normally but exhibit enhanced cell death after axonal injury. Nat Genet 1996; 13: 43-47.
62. Gurney ME, Pu H, Chiu AY, Dal Canto MC, Polchow CY, Alexander DD, et al. Motor neuron degeneration in mice that express a human Cu/Zn superoxide dismutase mutation. Science 1994; 264: 1772-1775.
63. Dobrowolny G, Aucello M, Rizzuto E, Beccafico S, Mammucari C, Bonconpagni S, et al. Skeletal muscle is a primary target of SOD1G93A-mediated toxicity. Cell Metab 2008; 8: 425-436.
64. Morrison BM, Lachey JL, Warsing LC, Ting BL, Pullen AE, Underwood KW, et al. A soluble activin type IIB receptor improves function in a mouse model of amyotrophic lateral sclerosis. Exp Neurol 2009; 217: 258-268.
65. Lee SJ. Regulation of muscle mass by myostatin. Annu Rev Cell Dev Biol 2004; 20: 61-86.
66. Lee SJ, McPherron AM. Regulation of myostatin activity and muscle growth. Proc Natl Acad Sci USA 2001; 98: 9306-9311.
67. Wolfman NM, McPherron AC, Pappano WN, Davies MV, Song K, Tomkinson KN, et al. Activation of latent myostatin by the BMP1/tolloid family of metalloproteinases. Proc Natl Acad Sci USA 2003; 100: 15842-15846.
68. Zimmers TA, Davies MV, Koniaris LG, Haynes P, Esquela AF, Tomkinson KN, et al. Induction of cachexia in mice by systemically administerd myostatin. Science. 2002; 296: 1486-1488
69. Langley B, Thomas M, Bishop A, Sharma M, Gilmour S, Kambadur, R. Myostatin inhibits myoblast differentiation by downregulating MyoD expression. J Biol Chem 2002; 277: 49831-49840.
70. Thomas M, Langley B, Berry C, Sharma M, Kirk S, Bass J, et al. Myostatin, a negative regulator of muscle growth, functions by inhibiting myoblast differentiation. J Biol Chem 2000; 275: 40235-40243.
71. Yang W, Zhang Y, Li Y, Wu Z, Zhu D. Myostatin induces cyclin D1 degradation to cause cell cycle arrest through a phosphatidylinositol 3-kinase/AKT/GSK-3_ pathway and is antagonized by insulin-like growth factor 1. J Biol Chem 2007; 282: 3799-3808.
72. Allen DL, Unterman TG. Regulation of myostatin expression and myoblast differentiation by FoxO and SMAD transcription factors. Am J Physiol Cell Physiol 2007; 292: C188-199.
73. Sakuma K, Watanabe K, Sano M, Uramoto I, Totsuka T. Differential adaptation of growth and differentiation factor 8/myostatin, fibroblast growth factor 6 and leukemia inhibitory factor in overloaded, regenerating, and denervated rat muscles. Biochim Biophys Acta Mol Cell Res 2000; 1497: 77-88.
74. Sakuma K, Watanabe K, Hotta N, Koike T, Ishida K, Katayama K, et al. The adaptive responses in several mediators linked with hypertrophy and atrophy of skeletal muscle after lower limb unloading in humans. Acta Physiol (Oxf) 2009; 197: 151-159.
75. Wehling M, Cai B, Tidball JG. Modulation of myostatin expression during modified muscle use. FASEB J 2000; 14: 103-110.
76. Gonzalez-Cadavid NF, Taylor WE, Yarasheski K, Sinha-Hikim I, Ma K, Ezzat S, et al. Organization of the human myostatin gene and expression in health men and HIV-infected men with muscle wasting. Proc Natl Acad Sci USA 1998; 95: 14938-43.
77. Kaspar, B. K., Mendell, J. R. Myostatin inhibition for enhancing muscle and/or improving muscle function. US20100178348 (2009).
78. Lee, S. -J., McPherron, A. C., Greenspan, D. S., Pappano, W. N., Wolfman, N., Tomkinson, K. Metalloprotease activation of myostatin, and methods of modulating myostatin activity. US7572599 (2010).
79. Hill, J. J., Wolfman, N. M. Follistatin domain containing proteins. US7572763 (2009).
80. Lee, S. -J., McPherron, A. C. Promyostatin peptides and methods of using same. US7566786 (2009).
81. Kambadur, R., Sharma, M., Senna Salerno, D. M. M., Berry, R. S., Siriett, V., Bower, R.S., Nicholas, G.D., McFarlane, C.D. Antimyostatin antibodies. US20090324590 (2009).
82. Han, B., Korytko, A., Mitchell, P.J., O'Bryan, L., Wang, R., Smith, R.C. Anti-myostatin antibodies. US7745583 (2010).
83. Han, H., De Paoli, A., Lu, J. Z.N., Wang, J.L. Uses of myostatin antagonists. US20070149458 (2007).
84. Glass, D.J., Clarke, B.A. Myostatin inhibiting fusion polypeptides and therapeutic methods thereof. US20060216279 (2006).
85. Knopf, J., Seehra, J. Methods of promoting growth of muscle tissue using ALK7. US7807631 (2010).
86. Bogdanovich S, Krag TO, Barton ER, Morris LD, Whittemore LA, Ahima RS, et al. Functional improvement of dystrophic muscle by myostatin blockade. Nature 2002; 420: 418-421.
87. Bradley L, Yaworsky PJ, Walsh FS. Myostatin as a therapeutic target for musculoskeletal disease. Cell Mol Life Sci 2008; 65: 2119-2124.
88. Holzbaur EL, Howland DS, Weber N, Wallace K, She Y, Kwak S, et al. Myostatin inhibition slows muscle atrophy in rodent models of amyotrophic lateral sclerosis. Neurobiol Dis 2006; 23: 697-707.
89. Whittemore LA, Song K, Li X, Aghajanian J, Davies MV, Girgenrath S, et al. Inhibition of myostatin in adult mice increases skeletal muscle mass and strength. Biochem Biophys Res Commun 2003; 300: 965-971.
90. Amthor H, Nicholas G, McKinnell I, Kemp CF, Sharma R, Kambadur R, et al. Follistatin complexes myostatin and antgonises myostatin-mediated inhibition of myogenesis. Dev Biol 2004; 270: 19-30.
91. Gilson H, Schakman O, Kalista S, Lause P, Tsuchida K, Thissen JP. Follistatin induces muscle hypertrophy through satellite cell proliferation and inhibiton of both myostatin and activin. Am J Physiol Endocrinol Metab 2009; 297: E157-E164.
92. Nakatani M, Takehara Y, Sugino H, Matsumoto M, Hashimoto O, Hasegawa Y, et al. Transgenic expression of a myostatin inhibitor derived from follistatin increases skeletal muscle mass and ameliorates dystrophic pathology in mdx mice. FASEB J 2008; 22: 477-487.
93. Haidet AM, Rizo L, Handy C, Umapathi P, Eagle A, Shilling C, et al. Long-term enhancement of skeletal muscle mass and strength by single gene administration of myostatin inhibitors. Proc Natl Acad Sci USA 2008; 105: 4318-4322.
94. Minetti GC, Colussi C, Adami R, Serra C, Mozzetta C, Parente V, et al. Functional and morphological recovery of dystrophic muscles in mice treated with deacetylase inhibitors. Nature Med 2006; 12: 1147-1150.
95. Brunelli S, Sciorati C, D'Antona G, Innocenzi A, Covarello D, Galvez BG, et al. Nitric oxide release combined with nonsteroidal anti-inflammatory activitiy prevents muscular dystrophy pathology and enhances stem cell therapy. Proc Natl Acad Sci USA 2007; 104: 264-269.
96. Ohsawa Y, Hagiwara H, Nakatani M, Yasue A, Moriyama K, Murakami T, et al. Muscular atrophy of caveolin-3-deficient mice is rescued by myostatin inhibition. J Clin Invest 2006; 11: 2924-2934.
97. Li ZF, Shelton GD, Engvall E. Elimination of myostatin does not combat muscular dystrophy in dy mice but increases postnatal lethality. Am J Pathol 2005; 166: 491-497.
98. Sakuma K, Nakao R, Inashima S, Hirata M, Kubo T, Yasuhara M. Marked reduction of focal adhesion kinase, serum response factor and myocyte enhancer factor 2C, but increase in RhoA and myostatin in the hindlimb dy mouse muscles. Acta Neuropath 2004; 108: 241-249.
99. Aghajanian, J., Wolfman, N.M., O'Hara, D., Davies, M.V., Veldman, G.M., Bridges, K.G., Whittemore, L.-A., Khurana, T.S., Bouxsein, M.L. Methods of increasing muscle mass or muscle strength using antibody inhibitors of GDF-8. US7731961 (2010).
100. Knopf, J., Seehra, J., Kumar, R. Variants derived from ActRIIB and uses therefore. US20090005308 (2009).
101. Whittemore, L.-A., Li, X. Therapeutic methods for muscular or neuromuscular disorders. US7785587 (2010).
102. Han, H., Min, H., Boone, T.C. Myostatin binding agents. US7511012 (2009).
103. Kambadur, R., Sharma, M., Hennebry, A., Senna Salerno, D.M.M., Berry, C.J., Siriett, V., Bower, R. S., Nicholas, G. D., McFarlane, C. D. Myostatin antagonists. WO2008016314 (2008).
104. Wagner KR, Fleckenstein JL, Amato AA, Barohn RJ, Bushby K, Escolar DM, et al. A phase I/II trial of MYO-029 in adult subjects with muscular dystrophy. Ann Neurol 2008; 63: 561-571.
105. Bogdanovich S, Perkins KJ, Krag TO, Whittemore LA, Khurana TS. Myostatin propeptide-mediated amelioration of dystrophic pathophysiology. FASEB J 2005; 19: 543-549.
106. Alter J, Lou F, Rabinowitz A, Yin H, Rosenfeld J, Wilton SD, et al. Systemic delivery of morpholino oligonucleotide restores dystrophin expression bodywide and improves dystrophic pathology. Nat Med 2006; 12: 175-177.
107. Lu QL, Rabinowitz A, Chen YC, Yokota T, Yin H, Alter J, et al. Systemic delivery of antisense oligoribonucleotide restores dystrophin expression in body-wide skeletal muscle. Proc Natl Acad Sci USA 2005; 102: 198-203.
108. Heemskerk HA, de Winter CL, de Kimpe SJ, van Kuik-Romeijn P, Heuvelmans N, Platenburg GJ, et al. In vivo comparison of 2_-Omethyl phosphorothioate and morpholino antisense oligonucleotides for Duchenne muscular dystrophy exon skipping. J Gene Med 2009; 11: 257-266.
109. Léger B, Derave W, De Bock K, Hespel P, Russell AP. Human sarcopenia reveals an increase in SOCS-3 and myostatin and a reduced efficiency of Akt phosphorylation. Rejuvenat Res 2008; 11:163-75.
110. Carlson ME, Hsu M, Conboy IM. Imbalance between pSmad3 and Notch induces CDK inhibitors is old muscle stem cells. Nature 2008; 454: 528-532.
111. Haddad F, Adams GR. Aging-sensitive cellular and molecular mechanisms associated with skeletal muscle hypertrophy. J Appl Physiol 2006, 100, 1188-1203.
112. Lebrasseur NK, Schelhorn TM, Bernardo BL, Cosgrove PG, Loria PM, Brown TA. Myostatin inhibition enhances the effects on performance and metabolic outcomes in aged mice. J Gerontol A Biol Sci Med Sci 2009; 64: 940-948.
113. Murphy KT, Koopman R, Naim T, Léger B, Trieu J, Ibebunjo C, et al. Antibody-directed myostatin inhibition in 21-mo-old mice reveals novel roles for myostatin signaling in skeletal muscle structure and function. FASEB J 2010; 24: 4433-4442.
114. Welle S, Burgess K, Mehta S. Stimulation of skeletal muscle myofibrillar protein synthesis, p70 S6 kinase phosphorylation, and ribosomal protein S6 phosphorylation by inhibition of myostatin in mature mice. Am J Physiol Endocrinol Metab 2009; 296: E567-E572.
115. Amirouche A, Durieux AC, Banzet S, Koulmann N, Bonnefoy R, Mouret C, et al. Down-regulation of Akt/mammalian target of rapamycin signaling pathway in response to myostatin overexpression in skeletal muscle. Endocrinolgy 2009; 150: 286-294.
116. Kambadur, R., Sharma, M., Hennebry, A., Senna Salerno, D. M. M. Use of myostatin (GDF-8) antagonists for treatment of sarcopenia (age-related muscle wasting). WO2006083183 (2009).
117. Costelli P, Muscaritoli M, Bonetto A, Penna F, Reffo P, Bossola M, et al. Muscle myostatin signaling is enhanced in experimental cancer cachexia. Eur J Clin Invest 2008; 38: 531-538.
118. Harada K, Shintani Y, Sakamoto Y, Wakatsuki M, Shitsukawa K, Saito S. Serum immunoreactive activin A levels in normal subjects and patients with various diseases. J Clin Endocrinol Metab 1996; 81: 2125-2130.
119. Sharma M, Kambadur R, Matthews KG, Somers WG, Devlin GP, Conaglen JV, et al. Myostatin, a transforming growth factor-beta superfamily member, is expressed in heart muscle and is upregulated in cardiomyocytes after infarct. J Cell Physiol 1999; 180: 1-9.
120. Shyu KG, Lu MJ, Wang BW, Sun HY, Chang H. Myostatin expression in ventricular myocardium in a rat model of volumeoverload heart failure. Eur J Clin Invest 2006; 36: 713-719.
121. Heineke J, Auger-Messier M, Xu J, Sargent M, York A, Welle S, et al. Genetic deletion of myostatin from the heart prevents skeletal muscle atrophy in heart failure. Circulation 2010; 121: 419-425.
122. Plant PJ, Brooks D, Faughnan M, Bayley T, Bain J, Singer L, et al. Cellular markers of muscle atrophy in chronic obstructive pulmonary disease (COPD). Am J Respir Cell Mol Biol 2010; 42: 461-471.
123. Testelmans D, Crul T, Maes K, Agten A, Comach M, Decramer M, et al. Atrophy and hypertrophy signaling in the diaphragm of patients with COPD. Eur Respir J 2010; 35: 549-556.
124. Hayot M, Rodriguez J, Vernus B, Carnac G, Jean E, Allen D, et al. Myostatin up-regulation is associated with the skeletal muscle response to hypoxic stimuli. Mol Cell Endocrinol 2011; 332: 38-47.
125. McFarlane C, Plummer E, Thomas M, Hennebry A, Ashby M, Ling N, et al. Myostatin induces cachexia by activating the ubiquitin proteolytic system through an NF-kB-independent, FoxO1-dependent mechanism. J Cell Physiol 2006; 209: 501-514.
126. Zhou X, Wang JL, Lu J, Song Y, Kwak KS, Jiao Q, et al. Reversal of cancer cachexia and muscle wasting by ActRIIB antagonism leads to prolonged survival. Cell 2010; 142: 531-543.
127. Klimek MEB, Aydogdu T, Link MJ, Pons M, Koniaris LG, Zimmers TA. Acute inhibition of myostatin-family proteins preserves skeletal muscle in mouse models of cancer cachexia. Biochem Biophys Res Commun 2010; 391: 1548-1554.
128. Lee SJ, Reed LA, Davies MV, Girgenrath S, Goad ME, Tomkinson KN, et al. Regulation of muscle growth by multiple ligands signaling through activin type II receptors. Proc Natl Acad Sci USA 2005; 102: 18117-22.
129. Klimek MEB, Aydogdu T, Link MJ, Pons M, Koniaris LG, Zimmers TA. Acute inhibition of myostatin-family proteins preserves skeletal muscle in mouse models of cancer cachexia. Biochem Biophys Res Commun 2010; 391: 1548-1554.
130. Bonetto A, Penna F, Minero VG, Reffo P, Bonelli G, Baccino FM, et al. Deacetylase inhibitors modulate the myostatin/follistatin axis without improving cachexia in tumor-bearing mice. Curr Cancer Drug Targets 2009; 9: 608-616.
131. Heineke J, Auger-Messier M, Xu J, Sargent M, York A, Welle S, et al. Genetic deletion of myostatin from the heart prevents skeletal muscle atrophy in heart failure. Circulation 2010; 121: 419-425.
132. McPherron AC, Lawler AM, Lee SJ. Regulation of skeletal muscle mass in mice by a new member TGF-beta superfamily member. Nature 1997; 387: 83-90.
133. Sharma M, Kambadur R, Matthews KG, Somers WG, Devlin GP, Conaglen JV, et al. Myostatin, a transforming growth factor-beta superfamily member, is expressed in heart muscle and is upregulated in cardiomyocytes after infarct. J Cell Physiol 1999 180: 1-9.
134. Allen DL, Cleary AS, Speaker KJ, Lindsay SF, Uyenishi J, Reed JM, et al. Myostatin, activin receptor IIb, and follistatin-like-3 gene expression are altered in adipose tissue and skeletal muscle of obese mice. Am J Physiol Endocrinol Metab 2008; 294: E918-E927.
135. Plant PJ, Brooks D, Faughnan M, Bayley T, Bain J, Singer L, et al. Cellular markers of muscle atrophy in chronic obstructive pulmonary disease (COPD). Am J Respir Cell Mol Biol 2010; 42: 461-471.
136. Hayot M, Rodriguez J, Vernus B, Carnac G, Jean E, Allen D, et al. Myostatin up-regulation is associated with the skeletal muscle response to hypoxic stimuli. Mol Cell Endocrinol 2011; 332: 38-47.
137. Dale, R.M.K. Compositions and methods for the treatment of muscle wasting. US20080119426 (2008).
138. Walsh, F. S., Zaleska, M. M., Howland, D. S., Holzbaur-Howland, E. L. F., Tchistiakova, L., Karim, R., Kelley, P., Kelley, W., Tan, X-. Y., Kwak, S. P., Wallace, K., Weber, N., Pangalos, M. N. Antagonist antibodies against GDF-8 and uses in treatment of ALS and other GDF-8-associated disorders. US20090285827 (2009).
139. Glickman MH, Ciechanover A. The ubiquitin-proteasome proteolytic pathway: Destruction for the sake of construction. Physiol Rev 2002; 82: 373-428.
140. Attaix D, Aurousseau E, Combaret L, Kee A, Larbaud D, Ralliére C, et al. Ubiquitin-proteasome-dependent proteolysis in skeletal muscle. Reprod Nutr Dev 1998; 38: 153-165.
141. Wray CJ, Tomkinson B, Robb BW, Hasselgren PO. Tripeptidylpeptidase II expression and activity are increased in skeletal muscle during sepsis. Biochem Biophys Res Commun 2002; 296: 41-47.
142. Smith IJ, Dodd SL. Calpain activation causes a proteasomedependent increase in protein degradation and inhibits the Akt signaling pathway in rat diaphragm muscle. Exp Physiol 2007; 92: 561-573.
143. Tisdale MJ. The ubiquitin-proteasome pathway as a therapeutic target for muscle wasting. J Support Oncol 2005; 3: 209-217.
144. Kwak KS, Zhou X, Solomon V, Baracos VE, Davis J, Bannon AW, et al. Regulation of protein catabolism by muscle-specific and cytokine-inducible ubiquitin ligase E3alpha-II during cancer cachexia. Cancer Res 2004; 64: 8193-8198.
145. Bodine SC, Latres E, Baumhueter S, Lai VK, Nunez L, Clarke BA, et al. Identification of ubiquitin ligases required for skeletal muscle atrophy. Science 2001; 294: 1704-1708.
146. Cai D, Frantz JD, Tawa NE Jr, Melendez PA, Oh BC, Lidov HG, et al. IKKbeta/ NF-kappaB activation causes severe muscle wasting in mice. Cell 2004; 119: 285-289.
147. Sandri M, Sandri C, Gilbert A, Skurk C, Calabria E, Picard A, et al. Foxo transcription factors induce the atrophy-related ubiquitin ligase atrogin-1 and cause skeletal muscle atrophy. Cell 2004; 117: 399-412.
148. Deshaies RJ. SCF and Cullin/Ring H2-based ubiquitin ligases. Annu Rev Cell Dev Biol 1999; 15: 435-467.
149. Coux O, Tanaka K, Goldberg AL. Structure and functions of the 20S and 26S proteasomes. Annu Rev Biochem 1996; 65: 801-847.
150. Rivett A. Proteasomes: Multicatalytic proteinase complexes. Biochem J 1993; 291: 1-10.
151. Baumeister W, Walz J, Zühl F, Seemüller E. The proteasome: Paradigm of a self-compartmentalizing protease. Cell 1998; 92: 367-380.
152. Glass DJ. Signaling pathways perturbing muscle mass. Curr Opin Clin Nutr Metabol Care 2010; 13: 225-229.
153. Latres E, Amini AR, Amini AA, Griffiths J, Martin FJ, Wei Y, et al. Insulin-like growth factor-1 (IGF-1) inversely regulates atrophy-induced genes via the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin (PI3K/Akt/ mTOR) pathway. J Biol Chem 2005; 280: 2737-2744.
154. Lee DH, Goldberg AL. Proteasome inhibitors: Valuable new tools for cell biologists. Trends Cell Biol 1998; 8: 397-403.
155. Nathan, C., Lin, G. Proteasome inhibitors and their use in treating pathogen infection and cancer. WO2009026579 (2009).
156. Olhava, E.J., Danca, M.D. Proteasome inhibitors. WO2009020448 (2009).
157. Kem, D.C., Patterson, E. Inhibitors of cardiac tachyarrhythmias. WO2005023187 (2005).
158. Kim, K.B., Ho, Y. K. Epoxyketone-based immunoproteasome inhibitors. US20080064659 (2008).
159. Gupta, S.K. New ubiquitin-proteasome regulating compounds and their application in cosmetic and pharmaceutical formulations. US20060269494 (2006).
160. Tortoriello, D., Weisberg, S.P. Selective proteasome inhibitors for treating diabetes. WO2008063513 (2008).
161. Brand, S.J. Methods and kits to treat chronic inflammatory immune diseases. WO2007002972 (2007).
162. Kisselev AF, Goldberg AL. Proteasome inhibitors: From research tools to drug candidates. Chem Biol 2001; 8: 739-758.
163. Holecek M, Muthny T, Kovarik M, Sispera L. Proteasome inhibitor MG-132 enhances whole-body protein turnover in rat. Biochem Biophys Res Commun 2006; 345: 38-42.
164. Bonuccelli G, Sotgia F, Schubert W, Park DS, Frank PG, Woodman SE, et al. Proteasome inhibitor (MG-132) treatment of mdx mice rescues the expression and membrane localization of dystrophin and dystrophin-associated proteins. Am J Pathol 2003; 163: 1663-1675.
165. Carmignac V, Quéré R, Durbeej M. Proteasome inhibition improves the muscle of laminin alpha2 chain-deficient mice. Hum Mol Genet 2011; 20: 541-552.
166. Adams J, Palombella VJ, Sausville EA. Proteasome inhibitors: A novel class of potent and effective antitumor agents. Cancer Res 1999, 59: 2615-2622.
167. van Hees HWH, Li Y-P, Ottenheijm CAC, Jin B, Pigmans CJC, Linkels M, et al. Proteasome inhibition improves diaphragm function in congestive heart failure rats. Am J Physiol Lung Cell Mol Physiol 2008; 294: L1260-L1268.
168. Supinski GS, Vanags J, Callahan LA. Effect of proteasome inhibitors on endotoxin-induced diaphragm dysfunction. Am J Physiol Lung Cell Mol Physiol 2009; 296: L994-1001.
169. Krawiec BJ, Frost RA, Vary TC, Jefferson LS, Lang CH. Hindlimb casting decreases muscle mass in part by proteasome-dependent proteolysis but independent of protein synthesis. Am J Physiol Endocrinol Metab 2005; 289: E969-980.
170. Bonuccelli G, Sotgia F, Capozza E, Gazzerro E, Minetti C, Lisanti MP. Localized treatment with a novel FDA-approved proteasome inhibitor blocks the degradation of dystrophin and dystrophinassociated proteins in mdx mice. Cell Cycle 2007; 6: 1242-1248.
171. Gazzerro E, Assereto S, Bonetto A, Sotgia F, Scarfi S, Pistorio A, et al. Therapeutic potential of proteasome inhibition in Duchenne and Becker muscular dystrophies. Am J Pathol 2010; 176: 1863-1877.
172. Beehler BC, Sleph PG, Benmassaoud L, Grover GJ. Reduction of skeletal muscle atrophy by a proteasome inhibitor in a rat model of denervation. Exp Biol Med 2006; 231: 335-41.
173. Bossola M, Pacelli F, Costelli P, Tortorelli A, Rosa F, Doglietto GB. Proteasome activities in the rectus abdominis muscle of young and older individuals. Biogerontology 2008; 9: 261-268.
174. Cai D, Lee KK, Li M, Tang MK, Chan KM. Ubiquitin expression is up-regulated in human and rat skeletal muscles during aging. Arch Biochem Biophys 2004; 425: 42-50.
175. Combaret L, Dardevet D, Béchet D, Taillandier D, Mosoni L, Attaix D. Skeletal muscle proteolysis in aging. Curr Opin Clin Nutr Metab Care 2009; 12: 37-41.
176. Pattison JS, Folk LC, Madsen RW, Childs TE, Booth FW. Transcriptional profiling identifies extensive downregulation of extracellular matrix gene expression in sarcopenic rat soleus muscle. Physiol Genomics 2003; 15: 34-43.
177. DeRuisseau KC, Kavazis AN, Powers SK. Selective downregulation of ubiquitin conjugation cascade mRNA occurs in the senescent rat soleus muscle. Exp Gerontol 2005; 40: 526-531.
178. Attaix D, Mosoni L, Dardevet D, Combaret L, Mirand PP, Grizard J. Altered responses in skeletal muscle protein turnover during aging in anabolic and catabolic periods. Int J Biochem Cell Biol 2005; 37: 1962-1973.
179. Husom AD, Peters EA, Kolling EA, Fugere NA, Thompson LV, Ferrington DA. Altered proteasome function and subunit composition in aged muscle. Arch Biochem Biophys 2004; 421: 67-76.
180. Khal J, Hine AV, Fearon KCH, Dejong CHC, Tisdale MJ. Increased expression of proteasome subunits in skeletal muscle of cancer patients with weight loss. Int J Biochem Cell Biol 2005; 37: 2196-2206.
181. Khal J, Wyke SM, Russell ST, Hine AV, Tisdale MJ. Expression of the ubiquitin-proteasome pathway and muscle loss in experimental cancer cachexia. Br J Cancer 2005; 93: 774-780.
182. Bossola M, Muscaritoli M, Costelli P, Bellantone R, Pacelli F, Busquets S, et al. Increased muscle ubiquitin mRNA levels in gastric cancer patients. Am J Physiol Regul Integr Comp Physiol 2001; 280: R1518-1523.
183. Bossola M, Muscaritoli M, Costelli P, Grieco G, Bonelli G, Pacelli F, et al. Increased muscle proteasome activity correlates with disease severity in gastric cancer patients. Ann Surg 2003; 237: 384-389.
184. Gomes MD, Lecker SH, Jagoe R, Navon A, Goldberg AL. Atrogin-1 a muscle specific F-box protein highly expressed during muscle atrophy. Proc Natl Acad Sci USA 2001; 98: 14440-14445.
185. Llovera M, Carbó N, García-Martínez C, Costelli P, Tessitore L, Baccino FM, et al. Anti-TNF treatment reverts increased muscle ubiquitin gene expression in tumour-bearing rats. Biochem Biophys Res Commun 1996; 221: 653-655.
186. Costelli P, Muscaritoli M, Bossola M, Penna F, Reffo P, Bonetto A, et al. IGF-1 is downregulated in experimental cancer cachexia. Am J Physiol Regul Integr Comp Physiol 2006; 291: R674-683.
187. Kumar NB, Kazi A, Smith T, Crocker T, Yu D, Reich RR, et al. Cancer cachexia: Traditional therapies and novel molecular mechanism-based approaches to treatment. Curr Treat Options Oncol 2010; 11: 107-117.
188. Kelley, R.F., Matsumoto, M. L. Methods and compositions for targeting polyubiquitin. US20090191209 (2009).
189. Gordon, N.C., Kelley, R.F., Pham, A. Methods and compositions for targeting polyubiquitin. US20100267050 (2010).